| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Phase I/II study of ipilimumab for patients with metastatic melanoma. | J Clin Oncol | 2008 | 2.79 |
| 2 | A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. | Invest New Drugs | 2010 | 2.09 |
| 3 | Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. | Sci Transl Med | 2014 | 1.30 |
| 4 | Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. | Clin Cancer Res | 2011 | 1.15 |